TITLE

Impressive response rate seen with three-drug regimen for multiple myeloma

AUTHOR(S)
Richards, Cassandra
PUB. DATE
October 2010
SOURCE
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the effectiveness of combining lenolidomide, bortezomib and dexamethasone in treating previously uncured multiple myeloma, which references a study by Paul G. Richardson and colleagues published in the journal "Blood."
ACCESSION #
54422829

 

Related Articles

  • Treatment of multiple myeloma changing rapidly. Adams, Stacey L.; Dickinson, Cara; Levitan, Dave; Shafer, Emily // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p38 

    This article reports that questions surrounding the changing field of multiple myeloma treatment emphasizes the need for large randomized trials, according to a study published in a 2008 issue of the "Journal of Clinical Oncology." William Bensinger of the Fred Hutcinson Cancer Research Center...

  • Alternating, sequential combination drug administration feasible in elderly patients with multiple myeloma. Leiser, Mark; Southall, Jennifer; Stott, Bob; Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p38 

    The article discusses a study led by Maria-Victoria Mateos on the feasibility of adding a combination of the drugs bortezomib, melphalan and prednison alternately or sequentially to lenalidomide plus dexamethasone to treat elderly patients with newly diagnosed multiple myeloma.

  • Multiple Myeloma: New Options, New Challenges. Lacy, Martha Q. // Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p877 

    The article focuses on the development concerning treatment of multiple myeloma. Along with the development is the emergence of new combination regimens in treating the disease. Some of the combination therapies are the pegylated liposomal doxorubicin, vincristine and decreased-frequency...

  • Addition of bortezomib to melphalan, prednisone improved OS in previously untreated multiple myeloma.  // Hem/Onc Today;5/10/2010, Vol. 11 Issue 9, p34 

    The article discusses research on the effectiveness of combining bortezomib with melphalan and prednisone in improving the overall survival of previously untreated patients with multiple myeloma, published in a 2010 issue of the "Journal of Clinical Oncology."

  • Combination therapies increased response rate in newly diagnosed multiple myeloma. Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p18 

    The article discusses research on the effectiveness of combination treatments in patients newly diagnosed from multiple myeloma, which references a study by Antonio Palumbo and colleagues presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October...

  • Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. Kourelis, T V; Kumar, S K; Srivastava, G; Gertz, M A; Lacy, M Q; Buadi, F K; Kyle, R A; Dispenzieri, A // Leukemia (08876924);Feb2014, Vol. 28 Issue 2, p455 

    A letter to the editor is presented which discusses the efficacy of immunomodulatory (Imid) drug Lenalidomide as treatment for patients with newly diagnosed multiple myeloma.

  • Lenalidomide plus dexamethasone most effective at first relapse for multiple myeloma.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p26 

    The article discusses research on the effectiveness of lenalidomide plus dexamethasone in treating first relapse for multiple myeloma, that references a study by E. A. Stadtmauer published in a 2009 issue of the "European Journal of Haematology."

  • MULTIPLE MYELOMA DRUGS PROMPT COST-EFFECTIVENESS NOTE. McCaffrey, Kevin // Medical Marketing & Media;Feb2016, Vol. 51 Issue 2, p16 

    The article focuses on the plan of the Institute for Clinical and Economic Review, a nonprofit organization, to evaluate the cost-effectiveness and efficacy of multiple myeloma drugs which have been approved by the U.S. Food and Drug Administration (FDA) such as Darzalex and Ninlaro.

  • NFκB pathway modeling for Optimal Drug Combination Therapy on Multiple Myeloma. Huiming Peng; Jianguo Wen; Hongwei Li; Chang, Jeff; Xiaobo Zhou // World Academy of Science, Engineering & Technology;May2010, Issue 41, p1087 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics